LS-125-2D4-11-10-1 [2D4]細胞
生長狀態： 懸浮生長
運輸方式： 凍存運輸
是否是腫瘤細胞： 0
物種來源： 小鼠
ATCC Number： HB-12644?
數量： 大量
細胞形態： **樣
**類型： IgG1 kappa
品系： BALB/c
LS-125-2D4-11-10-1 [2D4]細胞器官來源： 脾
年限： *****
Designations: LS-125-2D4-11-10-1 [2D4]
Depositors: Millennium Pharmaceuticals, Inc.
Isotype: IgG1 kappa
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma)
Morphology: lymphoblast
Source: LS-125-2D4-11-10-1 [2D4]細胞Organ: spleen
Strain: BALB/c
Cell Type: hybridoma:lymphoblast B lymphocyte;
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Age: *****
Comments: Animals were immunized with the murine pre-B cell line L1-2 expressing high levels of transfected human CCR1. Spleen cells were fused with Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 1 (CCR1).
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 1 ng/ml Interleukin-6 (IL-6), 90%; fetal bovine serum, 10%
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
LS-125-2D4-11-10-1 [2D4]細胞Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml.
Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 61431: Qin S, et al. LS-125-2D4-11-10-1 [2D4]細胞Anti-CCR1 antibodies and methods of use therefor . US Patent 6,329,510 dated Dec 11 2001
